The Top 15 R&D Budgets

In the world of drug development, you're only as good as your pipeline. As many companies' older blockbuster drugs go off-patent, analysts are looking at pipelines to see who'll have what it takes to survive and grow, and which companies will fall behind in the race to develop new drugs.

A recent EU report ranked the world's largest R&D budgets, and Pfizer took the lead--not just among drug developers but among all industries--with a staggering $8.34 billion budget in 2006. But as this report shows, spending more money doesn't necessarily make for a better pipeline. Take a look at this list of the top 15 pharmaceutical R&D budgets to find out how they're spending all those billions of dollars, who's keeping their edge, and who's falling behind.

1. Pfizer

2. Johnson & Johnson

3. GlaxoSmithKline

4. Sanofi-Aventis

5. Roche

6. Novartis

7. Merck

8. AstraZeneca

9. Amgen

10. Bayer

11. Eli Lilly

12. Wyeth

13. Bristol-Myers Squibb

14. Abbott

15. Schering-Plough


Vote for your favorite pipeline


Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.